Skip to content

Serbian Smoking Reduction/Cessation Trial (2SRT)

Randomized, Placebo-controlled, Double-blind, Phase IV Trial to Assess the Efficacy of a Traditional Swedish Smokeless Tobacco Product (Snus) to Reduce or Replace Cigarette Smoking Among Adult Smokers in Serbia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00601042
Acronym
2SRT
Enrollment
319
Registered
2008-01-25
Start date
2008-01-31
Completion date
2010-06-30
Last updated
2013-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cigarette Smoking

Keywords

smoking reduction, smoking cessation, randomized trial, Swedish snus, smokeless tobacco

Brief summary

The study aims to establish if a low-nitrosamine, smokeless tobacco product (Swedish snus) can help adult smokers to reduce and eventually completely quit smoking.

Interventions

OTHERSwedish snus (smokeless tobacco)

Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.

OTHEROnico

Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.

Sponsors

Swedish Match AB
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Male and female smokers in good general health aged 20-65 years regularly smoking \>10 cigarettes per day for more than 1 year who are motivated to reduce or quit smoking

Exclusion criteria

* Subjects with uncontrolled hypertension, history of coronary heart disease or other significant heart condition * History of other significant medical condition that might interfere with study procedures * Pregnant or nursing mother * Current drug abuse.

Design outcomes

Primary

MeasureTime frame
Smoking reduction defined as a reduction in self-reported number of smoked cigarettes per day >50% compared to base-line, verified by a reduction in CO in exhaled air of >1 ppm compared to base-line6 months

Secondary

MeasureTime frameDescription
Smoking cessation defined as self-reported total abstention from cigarettes verified by CO in exhaled air <10 ppm3, 6, 9 and 12 months
Clinical tests and biomarkers relevant for exposure to tobacco3, 6, 9, and 12 months
Smoking reduction12, 24, 36 and 48 monthsSmoking reduction according to self-report

Countries

Serbia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026